Impact of prophylaxis with CytoGam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients

Journal of Heart and Lung Transplantation

Volumn 22, Issue 7, 2003, Pages 754-763

  Kruger, Robert M ^a   Paranjothi, Subramanian ^a   Storch, Gregory A ^b   Lynch, John P ^a   Trulock, Elbert P ^a,c  

^a BARNES JEWISH HOSPITAL   (United States)

^b ST LOUIS CHILDREN S HOSPITAL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY;

ADULT; ARTICLE; BRONCHIOLITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; EVALUATION; FEMALE; GRAFT REJECTION; HUMAN; INCIDENCE; LUNG TRANSPLANTATION; MALE; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SEROLOGY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; VIREMIA; VIRUS DETECTION;

EID: 0037489513     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)00648-4     Document Type: Article

References (25)

1. Balfour H.H. Cytomegalovirus The troll of transplantation . Arch Intern Med. 139:1979;279-280.
2. Ettinger N.A., Bailey T.C., Trulock E.P., et al. Cytomegalovirus infection and pneumonitis impact after isolated lung transplantation . Am Rev Respir Dis. 147:1993;1017-1023.
3. Duncan S.R., Grgurich W.F., Iacono A.T., et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 150:1994;146-152.
4. Hertz M.I., Jordan C., Savik S.K., et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant. 17:1998;913-920.
5. Gutiérrez C.A., Chaparro C., Krajden M., Winton T., Kesten S. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest. 113:1998;924-932.
6. Egan J.J., Lomax J., Barber L., et al. Preemptive treatment for the prevention of cytomegalovirus disease. Transplantation. 65:1998;747-752.
7. Wreghitt T.G., Abel S.J.C., McNeil K., et al. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Transpl Int. 12:1999;254-260.
8. Gerbase M.W., Dubois D., Rothmeier C., Spiliopoulos A., Wunderli W., Nicod L.P. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Chest. 116:1999;1265-1272.
9. Kelly J., Hurley D., Raghu G. Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. J Heart Lung Transplant. 19:2000;355-359.
10. Valantine H.A., Luikart H., Doyle R., et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation A comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone . Transplantation. 72:2001;1647-1652.
11. Brumble L.M., Milstone A.P., Loyd J.E., et al. Prevention of cytomegalovirus infection and disease after lung transplantation Results using a unique regimen employing delayed ganciclovir . Chest. 121:2002;407-414.
12. Hosenpud J.D., Bennett L.E., Keck B.M., Boucek M.M., Novick R.J. The Registry of the International Society for Heart and Lung Transplantation eighteenth official report - 2001 . J Heart Lung Transplant. 20:2001;805-815.
13. Girgis R.A., Tu I., Berry G.J., et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant. 15:1996;1200-1208.
14. Kroshus T.J., Kshettry V.R., Savik K., John R., Hertz M.I., Bolman R.M. III. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg. 114:1997;195-202.
15. Heng D., Sharples L.D., McNeil K., Stewart S., Wreghitt T., Wallwork J. Bronchiolitis obliterans syndrome incidence, natural history, prognosis and risk factors . J Heart Lung Transplant. 17:1998;1255-1263.
16. Glowacki L.S., Smaill F.M. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients - a meta-analysis. Clin Transplant. 8:1994;10-18.
17. Snydman D.R., Werner B.G., Heinze-Lacey B., et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 17:1987;1049-1054.
18. Snydman D.R., Werner B.G., Dougherty N.N., et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation A randomized, double-blind, placebo-controlled trial . Ann Intern Med. 119:1993;984-991.
19. Maurer J.R., Snell G., de Hoyos A., Kesten S., Winton T. Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens. Transplant Proc. 25:1993;1434-1435.
20. Zamora M.R., Fullerton D.A., Campbell D.N., et al. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients. Transplant Proc. 26:1994;49-51.
21. Zamora M.R. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation. Transpl Infect Dis. 3:(suppl2):2001;49.
22. Kruger R.M., Shannon W.D., Arens M.Q., Lynch J.P., Storch G.A., Trulock E.P. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation. 68:1999;1272-1279.
23. Yousem S.A., Berry G.J., Brunt E.M., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection Lung Rejection Study Group . J Heart Transplant. 9:1990;593-601.
24. Yousem S.A., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection Lung Rejection Study Group . J Heart Lung Transplant. 15:1996;1-15.
25. Cooper J.D., Billingham M., Egan T., et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant. 12:1993;713-716.